Treatment of Temporal Arteritis (Giant Cell Arteritis)

Initial Treatment Approach

The American College of Rheumatology recommends starting high-dose oral glucocorticoids (prednisone 1 mg/kg/day, maximum 60 mg/day) immediately upon clinical suspicion of GCA, even before biopsy confirmation, to reduce the risk of vision loss and other complications 1, 2
For patients with threatened vision loss, the American College of Rheumatology suggests administering intravenous pulse methylprednisolone (500-1000 mg/day for 3 days) immediately, followed by high-dose oral prednisone (1 mg/kg/day) 3, 2

Diagnostic Confirmation

The American College of Rheumatology recommends arranging temporal artery biopsy as soon as possible, ideally within 2 weeks of starting glucocorticoids, to confirm diagnosis 4, 5
The American College of Rheumatology suggests obtaining a long-segment biopsy specimen (>1 cm) to improve diagnostic yield 6

Glucocorticoid Tapering

The European League Against Rheumatism recommends beginning gradual taper of glucocorticoids after 1 month of high-dose therapy, aiming for a dose of 10-15 mg/day by 3 months, and ≤5 mg/day after 1 year 4
The American College of Rheumatology advises guiding tapering by clinical symptoms and normalization of inflammatory markers 3

Adjunctive Therapy

The American College of Rheumatology recommends adding tocilizumab to glucocorticoids as first-line therapy, especially for patients at high risk of steroid-related complications, to reduce relapse rates and minimize steroid exposure 1
The American College of Rheumatology suggests considering methotrexate as an alternative steroid-sparing agent if tocilizumab is contraindicated, although the strength of evidence for this recommendation is moderate 7

Management of Relapses

The American College of Rheumatology recommends adding a non-glucocorticoid immunosuppressive agent and increasing glucocorticoid dose for disease relapse with cranial ischemic symptoms, with tocilizumab preferred over methotrexate for relapsing disease with cranial ischemia 7

Monitoring

The American College of Rheumatology recommends implementing long-term clinical monitoring for all patients, even those in apparent remission, to detect potential relapses and glucocorticoid-related adverse effects 7, 2
The American College of Rheumatology advises monitoring for glucocorticoid-related adverse effects and providing appropriate prophylaxis (e.g., bone protection) 4

Prognosis and Complications

The American Academy of Ophthalmology notes that without treatment, the risk of vision loss in the second eye is as high as 50% if one eye is already affected, highlighting the importance of prompt treatment 3
The American College of Rheumatology reports that visual loss occurs in 15-35% of patients with GCA, primarily before initiation of therapy, and that glucocorticoid-related adverse events are common (86% of patients) with long-term therapy 3, 4

Treatment for Temporal Arteritis (Giant Cell Arteritis)

Initial Treatment Approach

High-dose daily oral glucocorticoids with tocilizumab is strongly recommended for patients with GCA without visual symptoms/loss or critical cranial ischemia, as per the American College of Rheumatology 8
In some instances, glucocorticoids with methotrexate or glucocorticoids alone can be considered for patients with GCA without visual symptoms/loss or critical cranial ischemia, as per the American College of Rheumatology 8

Monitoring and Follow-up

For patients with an increase in inflammation markers alone (without clinical symptoms), clinical observation and monitoring without escalation of immunosuppressive therapy is recommended, according to the American College of Rheumatology 9

Initial Treatment for Temporal Arteritis (Giant Cell Arteritis)

Initial Treatment Approach

The American College of Rheumatology recommends daily dosing of glucocorticoids over alternate-day scheduling for patients with newly diagnosed GCA 10
For patients with newly diagnosed GCA without visual symptoms or cranial ischemia, high-dose oral glucocorticoids are the first-line treatment, with a recommended dose of prednisone 1 mg/kg/day (maximum 60 mg/day) 10

Diagnostic Confirmation

Temporal artery biopsy should be arranged as soon as possible, ideally within 2 weeks of starting glucocorticoids, to confirm diagnosis, and a long-segment biopsy specimen (>1 cm) is recommended to improve diagnostic yield 10
If temporal artery biopsy is negative but clinical suspicion remains high, noninvasive vascular imaging should be obtained to evaluate large vessel involvement 10

Steroid-Sparing Agents

The American College of Rheumatology recommends oral glucocorticoids combined with a non-glucocorticoid immunosuppressive agent, such as tocilizumab, for patients with active extracranial large vessel involvement 10

Initial Treatment for Suspected Giant Cell Arteritis

Immediate Treatment Algorithm

The American Heart Association recommends starting high-dose oral glucocorticoids (prednisone 40-60 mg daily or 1 mg/kg/day, maximum 60 mg) immediately upon clinical suspicion, even before obtaining temporal artery biopsy confirmation, for patients with suspected giant cell arteritis 11, 12
The American College of Cardiology suggests initiating oral prednisone 40-60 mg daily (or 1 mg/kg/day, maximum 60 mg) as a single morning dose immediately upon clinical suspicion for patients without visual symptoms or threatened vision loss 11
For patients with visual symptoms or threatened vision loss, the American Thoracic Society recommends administering intravenous methylprednisolone 500-1000 mg daily for 3 consecutive days immediately, followed by high-dose oral prednisone (1 mg/kg/day, maximum 60 mg) 13

Diagnostic Confirmation While on Treatment

The American Heart Association advises arranging temporal artery biopsy within 2 weeks of starting glucocorticoids to confirm diagnosis, and if temporal artery biopsy is negative but clinical suspicion remains high, obtaining CT or MRI imaging of the thoracic aorta and branch vessels to evaluate for large vessel involvement 12

Monitoring Disease Activity

The American College of Cardiology recommends assessing clinical symptoms (headache, jaw claudication, visual changes) and inflammatory markers (ESR, CRP) regularly, and physical examination should include temporal artery palpation and assessment for new ischemic symptoms 11, 12

Glucocorticoid Tapering Strategy

The American Heart Association suggests guiding tapering by clinical symptoms and normalization of ESR/CRP, with the goal of maintaining initial high-dose therapy for approximately 1 month until symptoms resolve and inflammatory markers normalize, then beginning gradual taper 11

Critical Pitfalls to Avoid

The American College of Cardiology warns against delaying treatment while awaiting biopsy confirmation, as vision loss is often irreversible, and against performing elective revascularization procedures until the acute inflammatory state is controlled and quiescent 11, 12

Management of Suspected Giant Cell Arteritis

Diagnostic Considerations

Dental evaluation is critical, as tooth infections can elevate ESR while CRP may remain normal, and dental pain with jaw involvement could mimic jaw claudication of GCA, according to the European League Against Rheumatism 14
New-onset persistent localized headache, especially in the temporal area, is a symptom that supports GCA diagnosis, as recommended by the American College of Rheumatology 14
True jaw claudication, which is pain with chewing that resolves with rest, versus dental pain that is constant, is a distinguishing feature of GCA, as noted by the European League Against Rheumatism 14
Constitutional symptoms, such as weight loss, low-grade fever, fatigue, and night sweats, can also support a diagnosis of GCA, according to the American College of Rheumatology 14

Treatment Approach

The American Heart Association recommends starting prednisone 40-60 mg daily (or 1 mg/kg/day, maximum 60 mg) as a single morning dose immediately if there is high clinical suspicion for GCA, despite normal CRP 15
If any visual symptoms are present, the American Academy of Neurology suggests giving IV methylprednisolone 500-1000 mg daily for 3 days first, then transitioning to oral prednisone 15
Arranging temporal artery biopsy within 2 weeks is crucial, as biopsy remains diagnostic even after starting steroids if performed within this window, as recommended by the American College of Rheumatology 16
Obtaining long-segment biopsy (>1 cm) can improve diagnostic yield, according to the European League Against Rheumatism 16

Diagnostic Testing

Temporal artery ultrasound, if expertise is available, can support GCA diagnosis with the halo sign, as noted by the American Institute of Ultrasound in Medicine 16
Dental panoramic radiograph or cone beam CT can evaluate tooth and surrounding bone, as recommended by the American Dental Association 14
Complete blood count and comprehensive metabolic panel can provide additional diagnostic information, according to the American College of Physicians 14

Monitoring and Tapering

Repeat ESR/CRP at 1 week to assess treatment response, as recommended by the European League Against Rheumatism 14
Guide steroid tapering by clinical symptoms and ESR/CRP normalization, rather than relying solely on inflammatory markers, as suggested by the American College of Rheumatology 14

Duration of Prednisone Therapy for Temporal Arteritis

Initial High-Dose Phase

The American College of Rheumatology recommends starting with high-dose prednisone (40-60 mg/day or 1 mg/kg/day, maximum 60 mg) immediately upon clinical suspicion, and maintaining this high dose for approximately 1 month until symptoms resolve and inflammatory markers (ESR/CRP) normalize 17, 18
For patients with visual symptoms or threatened vision loss, the European League Against Rheumatism (EULAR) suggests considering IV methylprednisolone 500-1000 mg/day for 3 days first, then transitioning to oral prednisone 18

Tapering Schedule

The European League Against Rheumatism (EULAR) recommends targeting ≤5 mg/day after 1 year, with a gradual tapering process guided by clinical symptoms and inflammatory markers, not by a fixed timeline 17
The tapering process should aim to reduce the dose to 15-20 mg/day within 2-3 months after achieving remission, and to ≤5 mg/day by 12 months 17

Adjunctive Therapy to Shorten Duration

The American College of Rheumatology suggests considering adding tocilizumab to glucocorticoids as first-line therapy to reduce relapse rates and minimize total steroid exposure 18
The European League Against Rheumatism (EULAR) recommends using methotrexate as an alternative steroid-sparing agent, though evidence is less robust than for tocilizumab, particularly for patients at high risk of steroid-related complications or those with refractory/relapsing disease 17, 18

Management of Temporal Arteritis After 52-Week Steroid Taper

Treatment and Monitoring

The American College of Rheumatology recommends continuing tapering glucocorticoids toward complete discontinuation, guided by clinical symptoms and inflammatory markers, while monitoring for relapse in patients with temporal arteritis after 52-week steroid taper with complete symptom resolution 19
The European League Against Rheumatism suggests that clinical assessment takes priority over laboratory values alone, and isolated elevation of ESR/CRP without clinical symptoms warrants observation and monitoring rather than escalation of therapy 20
Relapses occur in 34-75% of GCA patients during steroid tapering, and the American College of Rheumatology recommends increasing prednisone to 40-60 mg/day immediately in case of major relapse (cranial ischemic symptoms) 19
The American College of Rheumatology recommends adding tocilizumab as a steroid-sparing agent (preferred over methotrexate for relapsing disease with cranial symptoms) in case of major relapse (cranial ischemic symptoms) 20

Steroid-Sparing Agents

The American College of Rheumatology recommends considering adding tocilizumab or methotrexate to facilitate complete steroid discontinuation and prevent relapse in patients with temporal arteritis after 52-week steroid taper with complete symptom resolution 19
Tocilizumab (162 mg subcutaneously weekly) reduces relapse rates and allows faster steroid tapering, and is the preferred option 19

Imaging and Follow-up

The American Heart Association recommends periodic imaging for patients with known large-vessel involvement to assess for aneurysms, stenoses, and stability of lesions 20
Patients without large vessel involvement may not require routine repeated imaging 20

Treatment Duration

The American College of Cardiology recommends a typical total treatment duration of 1-2 years to avoid recurrence, though some patients may require longer therapy 21
The goal is sustained remission (absence of clinical signs/symptoms plus normal inflammatory markers) with ability to taper steroids without relapse 19